Sino Biopharmaceutical Limited 1177

Sino Biopharmaceutical Limited (HKEX: 01177), a leading innovation-driven pharmaceutical company in China, announced the launch of its new global brand, SBP Group, during its interim results meeting. SBP stands for Science, Breakthroughs and Patients: Science is where the company starts; breakthroughs are what it pursues; patients are why it does what it does. This philosophy aligns with the Company's mission, "Science for a Healthier World."

Sino Biopharmaceutical will receive an upfront payment of $200m from AstraZeneca.

The European stock markets closed sharply lower in Wednesday trading after fighting between the US a

The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions in the U.S.

GSK plc (NYSE:GSK) is one of the 12 Most Undervalued Stocks to Invest In. On May 18, 2026, GSK plc (NYSE:GSK) announced that the Japan’s Ministry of Health, Labour and Welfare expanded the eligible population for Arexvy to include adults aged 18 to 49 years at increased risk for RSV disease. GSK said Arexvy had […]

GSK (LSE:GSK) has entered a partnership with Sino Biopharmaceutical’s subsidiary CTTQ to launch and commercialize its hepatitis B treatment, bepirovirsen, in China. Bepirovirsen has received priority regulatory review status in China following Phase III trial results. The collaboration focuses on accelerating patient access to bepirovirsen across China’s large chronic hepatitis B population. GSK, trading at around £18.445, has returned 37.2% over the past year and 63.6% over the past five...

The European stock markets were mixed in Monday trading as The Stoxx Europe was 0.1% higher, Germany

May 11 (Reuters) - Britain's GSK said on Monday it signed a deal with Hong Kong-listed Sino Biopharmaceutical to expand its presence in the growing mainland China market and sell its experimental

The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called bepirovirsen that’s important to its future.

By blocking the JAK and ROCK pathways, rovadicitinib offers a differentiated mechanism of action to best-selling, single-target GVHD drugs like Jakavi and Imbruvica.

If you are wondering whether Sino Biopharmaceutical's current share price gives you good value, it helps to step back and look at how the market has been treating the stock recently and how that lines up with its fundamentals. The shares are currently at HK$7.00, with returns of 3.2% over the past week, 8.4% over the past month, 10.1% year to date, 152.6% over the past year and 56.4% over the past three years, while the five year return sits at a 5.4% decline. Recent news flow around Sino...

Phrontline Biopharma ("Phrontline"), a next-generation antibody–drug conjugate (ADC) company, today announced the closing of a $60 million Pre-A+ financing round. The round was led by Lapam Investment, with participation from Samsung Venture Investment Corporation (SVIC), Guofang Innovation, Hankang Venture Capital, Songqing Capital, Jifeng Ventures, and Sino Biopharmaceutical Limited. Existing shareholders — Decheng Capital, Medfine Health Fund, and C&D Emerging Investment — also participated a

Shanghai, November 10, 2025 – During the 8th China International Import Expo (CIIE), Sino Biopharmaceutical Limited ("Sino Biopharm") and Shanghai MediTrust Health Technology Group Co., Ltd. ("MediTrust Health") signed a strategic cooperation agreement. The two parties will carry out in-depth cooperation around innovative drugs and commercial insurance, jointly explore a new model of drug-insurance integration, and help more patients access high-quality, affordable medicines at an earlier stage.